🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuyang
Clinical trial register · China

Clinical Trials in Fuyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital5 AstraZeneca3 Capital Medical University3 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3 The Second Hospital of Anhui Medical University2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuyang

42 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
NCT07663526Crohn's Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
50
Fuyang, Zhengzhou, Zhoukou, Huaian, Yancheng, Meihekou, Shanghai
2026-08
Not yet open
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861Cirrhosis With Spontaneous Bacterial Peritonitis
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Not yet open
A Phase Ⅲ Clinical Study of SNA02-48 Injection
NCT07633119Tetanus
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Not yet open
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599Ischemic Cerebral Infarction
Beijing Tiantan Hospital
Phase 3
4,810
Fuyang, Wuhu, Beijing, Chongqing, Ningde, Dingxi, Jiuquan, Lanzhou
2026-04-22
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Guangzhou, Huizhou, Xinxiang, Hohhot
2026-02-11
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Active, closed
Efficacy and Safety of Home-based Structured Physical Exercise in Patients With Acute Ischemic Stroke
NCT07271082Acute Ischemic Stroke
Capital Medical University
Not applicable
208
Fuyang, Suzhou, Beijing, Zhoukou, Shihezi
2025-12-18
Recruiting
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308Acute Ischemic Stroke
Capital Medical University
Phase 3
1,192
Anqing, Bozhou, Fuyang, Ma’anshan, Suzhou, Wuhu, Beijing, Fuzhou
2025-12-18
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
130
Fuyang, Beijing, Ulanhot, Ürümqi
2025-10-10
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Active, closed
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267Hyperkalemia
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Not yet open
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861Acute Exacerbations of Bronchiectasis
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
China Liver Cancer Clinical Registry Cohort Database (HEAL)
NCT06777485Liver Cancer
Anhui Provincial Hospital
Observational
10,000
Anqing, Bengbu, Bozhou, Chizhou, Chuzhou, Fuyang, Hefei, Huaibei
2025-01-01
Recruiting
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06767800Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Recruiting
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
NCT06664021Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-16
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
NCT06673498Thrombocytopenia
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-10
Active, closed
Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis
NCT06615726Ischemic Stroke, Transient Ischemic Attack
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Active, closed
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526Chronic Kidney Disease
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT04974151Hypertension, MTHFR 677 TT Genotype
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
NCT06498622Hepatocellular Carcinoma
Anhui Provincial Hospital
Phase 2
45
Fuyang, Hefei
2024-07-20
Recruiting
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
NCT06449937Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
Anhui Provincial Hospital
Not applicable
130
Chuzhou, Fuyang, Hefei, Ma’anshan, Wuhu
2024-07
Recruiting
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
NCT06315231Post-stroke Cognitive Impairment
Simcere Pharmaceutical Co., Ltd
Phase 2
226
Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang
2024-04-08
Recruiting
Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion
NCT06155032Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
First Affiliated Hospital of Wannan Medical College
Not applicable
272
Fuyang, Hefei, Huainan, Huangshan City, Suzhou, Wuhu, Xiangyang
2024-01-04
Active, closed
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
NCT06175351Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Active, closed
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Active, closed
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
NCT05797714HBV Infection, Chronic Hepatitis b
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Fuyang.

How many clinical trials are recruiting in Fuyang?

25 of the 42 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuyang), 42 studies
PhaseStudiesRecruitingShare
Phase 315835.7%
Not applicable8519%
Phase 27616.7%
Phase 46214.3%
Observational224.8%
Phase 1/2214.8%
Phase 2/3214.8%

Most active sponsors

Lead sponsors with the most studies (Fuyang)
Lead sponsorStudiesRecruiting
Anhui Provincial Hospital55
AstraZeneca31
Capital Medical University31
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.32
Biogen22
Hangzhou Gensciences Biopharmaceutical Co., Ltd.20
Shenzhen Ausa Pharmed Co.,Ltd22
The Second Hospital of Anhui Medical University22
Beijing Tiantan Hospital10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.